Home :: Business :: FDA panel backs Puma Biotech’s breast cancer drug

FDA panel backs Puma Biotech’s breast cancer drug

REUTERS: Puma Biotechnology’s experimental breast cancer drug reduces the risk of the disease returning and should be approved, an advisory committee to the U.S. Food and Drug Administration concluded on Wednesday, paving the way for its approval in patients who have already had their tumors surgically removed.

The panel voted 12 to 4 in favor of the drug, neratinib, saying its benefits outweighed the risks, though they noted that the magnitude of the benefit was modest.

(Reporting by Toni Clarke in Washington)
Source: Reuters

Leave a Reply

Your email address will not be published. Required fields are marked *



Check Also

Blue economy: NIMASA awards staff, operators to promote professionalism, industry growth

.MAERSK, GAC, CHARKINS Others Bag NIMASA Achievement Awards .As agency awards its staff to promote ...